Biosion, a global, clinical-stage biotech committed to developing antibody-based therapies targeting immune and oncologic diseases, has announced the completion of a Series B financing round at upwards of RMB 100 million (USD 14.33 million). The funding was led by Guangfa Xinde Investment, with contributions from FangFund, Addor Capital, and Suxin Venture Capital.
Company Background and Pipeline
Founded in 2017, Biosion boasts a pipeline of innovative biologics through its internally derived proprietary technologies, including the H³ antibody discovery platform, SynTracer high-throughput endocytosis platform, and Flexibody bifunctional platform. Biosion’s lead asset, BSI-045B (anti-TSLP mAb), is currently in Phase II study for severe asthma and Phase I for atopic dermatitis.
Future Prospects and Strategic Plans
Biosion and its partners have plans to progress the immune-oncology and antibody drug conjugate-based portfolio into clinical trials for oncology indications over the next year. With operations in the US, Australia, and China, Biosion is well-positioned to leverage its global presence and innovative pipeline to address significant unmet medical needs in immune and oncologic diseases.-Fineline Info & Tech
